Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029711 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
A Phase 3 study of Severe Alopecia Areata, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 17
- Study locations
NCT07029711: Recruiting Phase 3 study of Severe Alopecia Areata, sponsored by Pfizer.
NCT07029711 is a Phase 3 study of Severe Alopecia Areata that is actively recruiting participants, run by Pfizer. The registered enrollment target is 225 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07029711, a Phase 3 study of Severe Alopecia Areata, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss. This study is seeking participants who have: * at least 50% scalp hair loss due to alopecia areata. * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. * history of clinical response failure to alopecia areata treatment (for children in EU/UK only). All participants in this study will receive either study medicine (ritlecitinib) or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. One-third of participants will receive ritlecitinib higher dose, one-third participants will receive ritlecitinib lower dose, and one-third participants will receive placebo. The study medicine is a capsule that is taken by mouth. It is taken once each day at home. The study will compare the experiences of participants receiving ritlecitinib to participants receiving placebo. This will help see if ritlecitinib is safe and effective. Participants will take part in this study for 6 months. During this time, they will have 8 study visits at the study clinic. The study team will also call participants about 8 times over the phone.
Primary Outcome
The difference in proportions of participants with the SALT ≤20 response at Week 24 between each ritlecitinib dose and placebo groups in pediatric AA participants defined by the inclusion and exclusion criteria.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ritlecitinib higher dose
- DRUG Ritlecitinib lower dose
Study Locations (17)
Nebraska
- Ear, Nose and Throat Consultants, LLC - Omaha
- Skin Specialists, PC dba Schlessinger MD - Omaha
- Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist) - Papillion
Texas
- 3A Research - West Location - El Paso
- Austin Institute for Clinical Research - Pflugerville
- Texas Dermatology and Laser Specialists - San Antonio
Florida
- Pediatric Skin Research - Miami
- D&H Tamarac Research Center - Tamarac
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Oregon
- Northwest Dermatology Institute - Portland
Utah
- AMR Clinical - Layton
Shanghai Municipality
- Huashan Hospital, Fudan University - Shanghai
Miyagi
- Tohoku University Hospital - Sendai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2025-07-31 |
| Est. Completion | 2027-05-18 |
| Phase | Phase 3 |
What NCT07029711 shows while recruiting
NCT07029711 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Severe Alopecia Areata appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07029711 lists 17 locations in 12 states (Nebraska, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT07029711 about?
NCT07029711 is a clinical study titled "A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata". The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss. This study is seeking participants who have: * at least 50% scalp hair loss due...
What is the current status of trial NCT07029711?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2025-07-31. Estimated completion is 2027-05-18.
What conditions does trial NCT07029711 study?
This clinical trial studies the following conditions: Severe Alopecia Areata.
What interventions are being tested in trial NCT07029711?
The interventions under investigation include: Placebo (DRUG), Ritlecitinib higher dose (DRUG), Ritlecitinib lower dose (DRUG).
Who is sponsoring clinical trial NCT07029711?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029711 being conducted?
This trial has 17 study locations across Florida, Indiana, Nebraska, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07029711's enrollment target sits among peer trials
225 1312th of 2000 higher than 684 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI